CD4 and melanoma: CD25-Foxp3+CD4 Tregs significantly increased in melanoma TILs and decreased in dLNs after treatment with anti-PD-1 but not anti-CD80 mAbs, implying PD-1 blockade prevented CD25−Foxp3+CD4 egress from tumor to dLNs.